Myasthenia and related disorders of the neuromuscular junction

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 81, Issue 8, 2010, Pages 850-857

  Spillane, Jennifer ^a   Beeson, David J ^b   Kullmann, Dimitri M ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIAMINOPYRIDINE; ACETYLCHOLINE; ATACICEPT; AUTOANTIBODY; AZATHIOPRINE; BOTULINUM TOXIN; CALCIUM CHANNEL; CHOLINERGIC RECEPTOR ANTIBODY; CHOLINESTERASE INHIBITOR; COMPLEMENT INHIBITOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ECULIZUMAB; EPHEDRINE; GUANIDINE; IMMUNOGLOBULIN; METHOTREXATE; MUSCLE SPECIFIC KINASE ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OFATUMUMAB; PREDNISOLONE; PREDNISONE; PYRIDOSTIGMINE; REV 576; RITUXIMAB; SALBUTAMOL; TACROLIMUS; UNCLASSIFIED DRUG; CHOLINERGIC RECEPTOR; IMMUNOSUPPRESSIVE AGENT; MUSK PROTEIN, HUMAN; PROTEIN TYROSINE KINASE;

ACETYLCHOLINE RELEASE; BONE MARROW SUPPRESSION; BOTULISM; CHOLINERGIC CRISIS; CLINICAL FEATURE; CLOSTRIDIUM BOTULINUM; CONGENITAL MYASTHENIC SYNDROME; CYTOPENIA; DISEASE CLASSIFICATION; DRUG MEGADOSE; EATON LAMBERT SYNDROME; EYE DISEASE; FUNCTION TEST; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HUMAN; HYPERHEMOGLOBINEMIA; HYPERSALIVATION; IMMUNOPATHOGENESIS; INFECTION RISK; KIDNEY FAILURE; LIVER TOXICITY; LYMPHOPROLIFERATIVE DISEASE; MUSCLE FATIGUE; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; MYASTHENIC CRISIS; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUROMUSCULAR JUNCTION DISORDER; NEUROMUSCULAR SYNAPSE; NEUTROPENIA; NONHUMAN; PARANEOPLASTIC NEUROPATHY; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SYNAPTIC TRANSMISSION; THYMECTOMY; THYMOMA; UNSPECIFIED SIDE EFFECT; IMMUNOLOGY; LAMBERT-EATON MYASTHENIC SYNDROME; METABOLISM; MYASTHENIC SYNDROMES, CONGENITAL; NERVE CONDUCTION; PATHOLOGY; PHYSIOLOGY;

BOTULISM; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LAMBERT-EATON MYASTHENIC SYNDROME; MYASTHENIA GRAVIS; MYASTHENIC SYNDROMES, CONGENITAL; NEURAL CONDUCTION; NEUROMUSCULAR JUNCTION; PROGNOSIS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, CHOLINERGIC; SYNAPTIC TRANSMISSION;

EID: 77955732317     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2008.169367     Document Type: Review

References (111)

1. Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: past, present, and future. J Clin Invest 2006;116:2843-54.
2. Vincent. Autoimmune disorders of the neuromuscular junction. 2008. http://www. neurologyindia.com/article.asp?issn=0028-3886;year=2008;volume- 56;issue=3; spage=305;epage=313;aulast=Vincent (accessed 8 Jul 2009).
3. Alshekhlee A, Miles JD, Katirji B, et al. Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals. Neurology 2009;72:1548-54.
4. Robertson NP, Deans J, Compston DA. Myasthenia gravis: a population based epidemiological study in Cambridgeshire, England. J Neurol Neurosurg Psychiatry 1998;65:492-6.
5. Phillips LH. The epidemiology of myasthenia gravis. Ann N Y Acad Sci 2003;998:407-12.
6. Vincent A, Clover L, Buckley C, et al. Evidence of underdiagnosis of myasthenia gravis in older people. J Neurol Neurosurg Psychiatry 2003;74:1105-8.
7. Vincent A. Unravelling the pathogenesis of myasthenia gravis. Nat Rev Immunol 2002;2:797-804.
8. Fambrough DM, Drachman DB, Satyamurti S. Neuromuscular junction in myasthenia gravis: decreased acetylcholine receptors. Science 1973;182:293-5.
9. Toyka KV, Drachman DB, Griffin DE, et al. Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice. N Engl J Med 1977;296:125-31.
10. Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 2009;8:475-90.
11. Mygland A, Aarli JA, Matre R, et al. Ryanodine receptor antibodies related to severity of thymoma associated myasthenia gravis. J Neurol Neurosurg Psychiatry 1994;57:843-6.
12. Skeie GO, Romi F. Paraneoplastic myasthenia gravis: immunological and clinical aspects. Eur J Neurol 2008;15:1029-33.
13. Grob D, Brunner N, Namba T, et al. Lifetime course of myasthenia gravis. Muscle Nerve 2008;37:141-9.
14. Grob D, Arsura EL, Brunner NG, et al. The course of myasthenia gravis and therapies affecting outcome. Ann N Y Acad Sci 1987;505:472-99.
15. Barohn RJ. Treatment and clinical research in myasthenia gravis: how far have we come? Ann N Y Acad Sci 2008;1132:225-32.
16. Barohn RJ. Standards of measurements in myasthenia gravis. Ann N Y Acad Sci 2003;998:432-9.
17. Jaretzki A, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 2000;55:16-23.
18. Sethi KD, Rivner MH, Swift TR. Ice pack test for myasthenia gravis. Neurology 1987;37:1383-5.
19. Meriggioli MN, Sanders DB. Advances in the diagnosis of neuromuscular junction disorders. Am J Phys Med Rehabil 2005;84:627-38.
20. AAEM Quality Assurance Committee. American Association of Electrodiagnostic Medicine. Literature review of the usefulness of repetitive nerve stimulation and single fiber EMG in the electrodiagnostic evaluation of patients with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome. Muscle Nerve 2001;24:1239-47.
21. Padua L, Stalberg E, LoMonaco M, et al. SFEMG in ocular myasthenia gravis diagnosis. Clin Neurophysiol 2000;111:1203-7.
22. Meriggioli MN. Myasthenia gravis with anti-acetylcholine receptor antibodies. Front Neurol Neurosci 2009;26:94-108.
23. Chan KH, Lachance DH, Harper CM, et al. Frequency of seronegativity in adult-acquired generalized myasthenia gravis. Muscle Nerve 2007;36:651-8.
24. Vincent A, Leite MI, Farrugia ME, et al. Myasthenia gravis seronegative for acetylcholine receptor antibodies. Ann N Y Acad Sci 2008;1132:84-92. (Pubitemid 351841363)
25. Vincent A, Leite MI. Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis. Curr Opin Neurol 2005;18:519-25.
26. Lavrnic D, Losen M, Vujic A, et al. The features of myasthenia gravis with autoantibodies to MuSK. J Neurol Neurosurg Psychiatry 2005;76:1099-102.
27. Shiraishi H, Motomura M, Yoshimura T, et al. Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis. Ann Neurol 2005;57:289-93.
28. Kong XC, Barzaghi P, Ruegg MA. Inhibition of synapse assembly in mammalian muscle in vivo by RNA interference. EMBO Rep 2004;5:183-8.
29. Leite MI, Jacob S, Viegas S, et al. IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis. Brain 2008;131(7 Pt):1940-52.
30. Skeie GO, Apostolski S, Evoli A, et al. Guidelines for the treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 2006;13:691-9.
31. Schneider-Gold C, Gajdos P, Toyka KV, et al. Corticosteroids for myasthenia gravis. Database Syst Rev 2005;(2):CD002828.
32. Sathasivam S. Steroids and immunosuppressant drugs in myasthenia gravis. Nat Clin Pract Neurol 2008;4:317-27.
33. Sommer N, Sigg B, Melms A, et al. Ocular myasthenia gravis: response to long-term immunosuppressive treatment. J Neurol Neurosurg Psychiatry 1997;62:156-62.
34. Hart IK, Sharshar T, Sathasivam S. Immunosuppressant drugs for myasthenia gravis. J Neurol Neurosurg Psychiatry 2009;80:5-6; discussion 6.
35. Anon. A randomised clinical trial comparing prednisone and azathioprine in myasthenia gravis. Results of the second interim analysis. Myasthenia Gravis Clinical Study Group. J Neurol Neurosurg Psychiatry 1993;56:1157-63.
36. Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology 1998;50:1778-83.
37. Gedizlioglu M, Coban P, Ce P, et al. An unusual complication of immunosuppression in myasthenia gravis: progressive multifocal leukoencephalopathy. Neuromuscul Disord 2009;19:155-7.
38. Tindall RS, Phillips JT, Rollins JA, et al. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann N Y Acad Sci 1993;681:539-51.
39. Hart IK, Sathasivam S, Sharshar T. Immunosuppressive agents for myasthenia gravis. Cochrane Database Syst Rev 2007;(4):CD005224.
40. Nagane Y, Utsugisawa K, Obara D, et al. Efficacy of low-dose FK506 in the treatment of Myasthenia gravis - a randomized pilot study. Eur Neurol 2005;53:146-50.
41. Drachman DB, Jones RJ, Brodsky RA. Treatment of refractory myasthenia: 'rebooting' with high-dose cyclophosphamide. Ann Neurol 2003;53:29-34.
42. Heatwole C, Ciafaloni E. Mycophenolate mofetil for myasthenia gravis: a clear and present controversy. Neuropsychiatr Dis Treat 2008;4:1203-9.
43. Hauser RA, Malek AR, Rosen R. Successful treatment of a patient with severe refractory myasthenia gravis using mycophenolate mofetil. Neurology 1998;51:912-13.
44. Chaudhry V, Cornblath DR, Griffin JW, et al. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology 2001;56:94-6.
45. Meriggioli MN, Ciafaloni E, Al-Hayk KA, et al. Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability. Neurology 2003;61:1438-40.
46. Muscle Study Group. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology 2008;71:394-9.
47. Sanders DB, Hart IK, Mantegazza R, et al. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology 2008;71:400-6.
48. Gajdos P, Chevret S, Clair B, et al. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann Neurol 1997;41:789-96.
49. Gajdos P, Chevret S, Toyka K. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev 2003;(2):CD002277.
50. Gajdos P, Chevret S, Toyka K. Plasma exchange for myasthenia gravis. Cochrane Database Syst Rev 2002;(4):CD002275.
51. Zinman L, Ng E, Bril V. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology 2007;68:837-41.
52. Illa I, Diaz-Manera J, Rojas-Garcia R, et al. Sustained response to Rituximab in anti- AChR and anti-MuSK positive Myasthenia Gravis patients. J Neuroimmunol 2008;201-202:90-4.
53. Stübgen J. B cell-targeted therapy with rituximab and autoimmune neuromuscular disorders. J Neuroimmunol 2008;204:1-12.
54. Lebrun C, Bourg V, Tieulie N, et al. Successful treatment of refractory generalized myasthenia gravis with rituximab. Eur J Neurol 2009;16:246-50.
55. Nelson RP, Pascuzzi RM, Kessler K, et al. Rituximab for the treatment of thymoma-associated and de novo myasthenia gravis: 3 cases and review. J Clin Neuromuscul Dis 2009;10:170-7.
56. Gold R, Schneider-Gold C. Current and future standards in treatment of myasthenia gravis. Neurotherapeutics 2008;5:535-41.
57. Sieb JP. Myasthenia gravis: emerging new therapy options. Curr Opin Pharmacol 2005;5:303-7.
58. Soltys J, Kusner LL, Young A, et al. Novel complement inhibitor limits severity of experimentally myasthenia gravis. Ann Neurol 2009;65:67-75.
59. Bachmann K, Burkhardt D, Schreiter I, et al. Thymectomy is more effective than conservative treatment for myasthenia gravis regarding outcome and clinical improvement. Surgery 2009;145:392-8.
60. Gronseth GS, Barohn RJ. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;55:7-15.
61. Gronseth G, Barohn R. Thymectomy for myasthenia gravis. Curr Treat Options Neurol 2002;4:203-9.
62. Díaz-Manera J, Rojas-García R, Illa I. Treatment strategies for myasthenia gravis. Expert Opin Pharmacother 2009;10:1329-42.
63. Meyer DM, Herbert MA, Sobhani NC, et al. Comparative clinical outcomes of thymectomy for myasthenia gravis performed by extended transsternal and minimally invasive approaches. Ann Thorac Surg 2009;87:385-90; discussion 390-1.
64. Soltys J, Gong B, Kaminski HJ, et al. Extraocular muscle susceptibility to myasthenia gravis: unique immunological environment? Ann N Y Acad Sci 2008;1132:220-4.
65. Kupersmith MJ, Ying G. Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment. Br J Ophthalmol 2005;89:1330-4.
66. Benatar M, Kaminski HJ. Evidence report: the medical treatment of ocular myasthenia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2007;68:2144-9.
67. Kupersmith M. Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-up. J Neurol 2009. http://www.ncbi.nlm.nih. gov/pubmed/19377863 (accessed 17 Jul 2009).
68. Benatar M, Kaminski H. Medical and surgical treatment for ocular myasthenia. Cochrane Database Syst Rev 2006;(2):CD005081.
69. Jani-Acsadi A, Lisak RP. Myasthenic crisis: guidelines for prevention and treatment. J Neurol Sci 2007;261:127-33.
70. Rózsa C, Mikor A, Kasa K, et al. Long-term effects of combined immunosuppressive treatment on myasthenic crisis. Eur J Neurol 2009. http:// www.ncbi.nlm.nih.gov/pubmed/19453406 (accessed 17 Jul 2009).
71. Petty R. Lambert Eaton myasthenic syndrome. Pract Neurol 2007;7:265-7.
72. Sanders DB. Lambert-Eaton myasthenic syndrome: diagnosis and treatment. Ann N Y Acad Sci 2003;998:500-8.
73. Wirtz PW, Bradshaw J, Wintzen AR. Vershuuren JJ association autoimmune diseases in patients with Lambert-Eaton myashtenic syndrome and their families. J Neurol 2004;25:1255-9.
74. Titulaer MJ, Wirtz PW, Willems LNA, et al. Screening for small-cell lung cancer: a follow-up study of patients with Lambert-Eaton myasthenic syndrome. J Clin Oncol 2008;26:4276-81.
75. Tschernatsch M, Gross O, Kneifel N, et al. SOX-1 autoantibodies in patients with paraneoplastic neurological syndromes. Autoimmun Rev 2009;8:549-51.
76. Oh SJ, Kurokawa K, Claussen GC, et al. Electrophysiological diagnostic criteria of Lambert-Eaton myasthenic syndrome. Muscle Nerve 2005;32:515-20.
77. Lang B, Vincent A. Autoimmune disorders of the neuromuscular junction. Curr Opin Pharmacol 2009;9:336-40.
78. Maddison P, Newsom-Davis J. Treatment for Lambert-Eaton myasthenic syndrome. Cochrane Database Syst Rev 2003;(2):CD003279.
79. Verschuuren JJGM, Wirtz PW, Titulaer MJ, et al. Available treatment options for the management of Lambert-Eaton myasthenic syndrome. Expert Opin Pharmacother 2006;7:1323-36.
80. Lang B, Pinto A, Giovannini F, et al. Pathogenic autoantibodies in the Lambert-Eaton myasthenic syndrome. Ann N Y Acad Sci 2003;998:187-95.
81. Illa I. IVIg in myasthenia gravis, Lambert Eaton myasthenic syndrome and inflammatory myopathies: current status. J Neurol 2005;252(Suppl 1):I14-18.
82. Pellkofer HL, Voltz R, Kuempfel T. Favorable response to rituximab in a patient with anti-VGCC-positive Lambert-Eaton myasthenic syndrome and cerebellar dysfunction. Muscle Nerve 2009;40:305-8.
83. Sobel J. Botulism. Clin Infect Dis 2005;41:1167-73.
84. Shapiro RL, Hatheway C, Swerdlow DL. Botulism in the United States: a clinical and epidemiologic review. Ann Intern Med 1998;129:221-8.
85. McLauchlin J, Grant KA, Little CL. Food-borne botulism in the United Kingdom. J Public Health (Oxf) 2006;28:337-42.
86. Crowner BE, Brunstrom JE, Racette BA. Iatrogenic botulism due to therapeutic botulinumtoxin a injection in a pediatric patient. Clin Neuropharmacol 2007;30:310-13.
87. Chertow DS, Tan ET, Maslanka SE, et al. Botulism in 4 adults following cosmetic injections with an unlicensed, highly concentrated botulinum preparation. JAMA 2006;296:2476-9.
88. Engel A, Shen X, Selcen D, et al. What have we learned from the congenital myasthenic syndromes. J Mol Neurosci 2009. http://www.ncbi.nlm.nih. gov/pubmed/19688192 (accessed 11 Oct 2009).
89. Ohno K, Brengman J, Tsujino A, et al. Human endplate acetylcholinesterase deficiency caused by mutations in the collagen-like tail subunit (ColQ) of the asymmetric enzyme. Proc Natl Acad Sci U S A 1998;95:9654-9.
90. Donger C, Krejci E, Serradell AP, et al. Mutation in the human acetylcholinesterase-associated collagen gene, COLQ, is responsible for congenital myasthenic syndrome with end-plate acetylcholinesterase deficiency (Type Ic). Am J Hum Genet 1998;63:967-75.
91. Ohno K, Tsujino A, Brengman JM, et al. Choline acetyltransferase mutations cause myasthenic syndrome associated with episodic apnea in humans. Proc Natl Acad Sci U S A 2001;98:2017-22.
92. Sanes JR, Lichtman JW. Induction, assembly, maturation and maintenance of a postsynaptic apparatus. Nat Rev Neurosci 2001;2:791-805.
93. Kummer TT, Misgeld T, Sanes JR. Assembly of the postsynaptic membrane at the neuromuscular junction: paradigm lost. Curr Opin Neurobiol 2006;16:74-82.
94. Okada K, Inoue A, Okada M, et al. The muscle protein Dok-7 is essential for neuromuscular synaptogenesis. Science 2006;312:1802-5.
95. Chevessier F, Faraut B, Ravel-Chapuis A, et al. MUSK, a new target for mutations causing congenital myasthenic syndrome. Hum Mol Genet 2004;13:3229-40.
96. Ohno K, Sadeh M, Blatt I, et al. E-box mutations in the RAPSN promoter region in eight cases with congenital myasthenic syndrome. Hum Mol Genet 2003;12:739-48.
97. Burke G, Cossins J, Maxwell S, et al. Rapsyn mutations in hereditary myasthenia: distinct early- and late-onset phenotypes. Neurology 2003;61:826-8.
98. Müller JS, Mildner G, Müller-Felber W, et al. Rapsyn N88K is a frequent cause of congenital myasthenic syndromes in European patients. Neurology 2003;60:1805-10.
99. Maselli RA, Dunne V, Pascual-Pascual SI, et al. Rapsyn mutations in myasthenic syndrome due to impaired receptor clustering. Muscle Nerve 2003;28:293-301.
100. Beeson D, Higuchi O, Palace J, et al. Dok-7 mutations underlie a neuromuscular junction synaptopathy. Science 2006;313:1975-8.
101. Palace J, Lashley D, Newsom-Davis J, et al. Clinical features of the DOK7 neuromuscular junction synaptopathy. Brain 2007;130(6 Pt):1507-15.
102. Müller JS, Herczegfalvi A, Vilchez JJ, et al. Phenotypical spectrum of DOK7 mutations in congenital myasthenic syndromes. Brain 2007;130(6 Pt):1497-506.
103. Müller JS, Abicht A, Burke G, et al. The congenital myasthenic syndrome mutation RAPSN N88K derives from an ancient Indo-European founder. J Med Genet 2004;41:e104.
104. Michalk A, Stricker S, Becker J, et al. Acetylcholine receptor pathway mutations explain various fetal akinesia deformation sequence disorders. Am J Hum Genet 2008;82:464-76.
105. Vogt J, Harrison BJ, Spearman H, et al. Mutation analysis of CHRNA1, CHRNB1, CHRND, and RAPSN genes in multiple pterygium syndrome/fetal akinesia patients. Am J Hum Genet 2008;82:222-7.
106. Maselli RA, Ng JJ, Anderson JA, et al. Mutations in LAMB2 causing a severe form of synaptic congenital myasthenic syndrome. J Med Genet 2009;46:203-8.
107. Harper CM, Engel AG. Quinidine sulfate therapy for the slow-channel congenital myasthenic syndrome. Ann Neurol 1998;43:480-4.
108. Harper CM, Fukodome T, Engel AG. Treatment of slow-channel congenital myasthenic syndrome with fluoxetine. Neurology 2003;60:1710-13.
109. Bestue-Cardiel M, Sáenz de Cabezón-Alvarez A, Capablo-Liesa JL, et al. Congenital endplate acetylcholinesterase deficiency responsive to ephedrine. Neurology 2005;65:144-6.
110. Mihaylova V, Müller JS, Vilchez JJ, et al. Clinical and molecular genetic findings in COLQ-mutant congenital myasthenic syndromes. Brain 2008;131(3 Pt):747-59.
111. Selcen D, Milone M, Shen X, et al. Dok-7 myasthenia: phenotypic and molecular genetic studies in 16 patients. Ann Neurol 2008;64:71-87.